Research on treating disease with medication. Covers psychedelics, combination cancer therapy, opioid treatment in pregnancy, and personalized guidelines.
A global, multicenter study has found CAR T-cell therapy to be safe and effective in treating patients with relapsed or refractory B-cell ALL. The therapy achieved an overall remission rate of 81% within 3 months of treatment, with a median length of remission lasting up to 20 months.
Researchers aim to prevent, slow or reverse muscle breakdown with a new drug compound and nano-channel delivery system. The implantable device will provide constant, steady drug delivery without injections or pills.
The new guideline increases the window of time for selected patients to receive mechanical thrombectomy for large vessel strokes, up to 16 hours after a stroke. It also broadens eligibility for administering a clot-busting IV drug called alteplase, potentially increasing the number of people receiving intravenous clot-busting treatment.
The study found that only 27.6% of individuals with anxiety disorders received appropriate treatment, with the remaining cases receiving inadequate care. The low treatment rate is attributed to factors such as lack of awareness, health system weaknesses, and stigma surrounding mental illnesses.
The study tested a new combination of gemcitabine and sirolimus in patients with sarcomas, showing a 44% rate of patients free of progression at 3 months. Researchers believe the treatment's positive results warrant further evaluation in subsequent studies.
A new study published in Military Medicine found that veterans who learned Transcendental Meditation experienced significant reductions in PTSD symptoms after just one month. The study involved 41 veterans and 5 active-duty soldiers, with 80% showing clinically significant decreases in symptoms.
A preliminary study suggests that CranioSacral Therapy can improve range of motion, pain, sleep, and cognitive function in ex-NFL players with concussion and mild TBI. More clinical research data is needed to understand its effectiveness in treating post-concussive syndrome and potentially chronic traumatic encephalopathy.
Vanderbilt University and Lundbeck are collaborating on a novel approach to treating schizophrenia. The Vanderbilt compounds, developed with support from the National Institute of Mental Health, have shown antipsychotic-like effects and improved cognitive performance in animal models.
A new USC study reveals that tumor growth properties can influence response to cancer drugs. Researchers found certain parameters of tumor growth can forecast the effectiveness of anti-angiogenic treatment, allowing for more accurate predictions. This breakthrough has the potential to improve cancer therapy outcomes.
A study found that high out-of-pocket costs for oral cancer medications lead to prescription abandonment, even among those with insurance. Patients faced with costs over $2,000 were more likely to abandon their prescriptions, highlighting the need for strategies to improve patient access.
A new study found that factors such as persistent symptoms, comorbidities, leisure-time physical activity, and financial challenges affect health-related quality of life in older adults with cancer. The research highlights the importance of comprehensive care that addresses these factors to improve outcomes for this vulnerable population.
A new 'checkpoint' model can identify potential drugs to treat genetic disorders by allowing compounds to bypass premature stop instructions once, reducing the risk of harmful protein generation. The model has been used to screen hundreds of genes and existing FDA-approved drugs, identifying two promising targets for drug development.
A team of researchers identified a molecular mechanism leading to ART treatment failures in malaria parasites, finding that blocking a specific stress pathway prevents latent stage entry. This breakthrough could lead to the development of new approaches to combat malaria by preventing treatment failure.
A team of researchers at the University of Montreal Hospital Research Centre has discovered a promising solution to improving treatments for cystic fibrosis. By adding quorum-sensing inhibitors to current drugs, they were able to restore treatment efficacy in cells of cystic fibrosis patients.
A meta-analysis of trials involving nearly 5,000 patients found no differences in mortality between percutaneous coronary intervention and coronary artery bypass grafting. Percutaneous coronary intervention is less burdensome on patients, enabling rapid return to work without long-term hospitalization.
A landmark clinical trial has shown impressive results for a CAR-T cancer treatment in refractory large B-cell lymphoma patients, achieving complete remission in 42% of cases. However, severe side effects including cytokine release syndrome and neurologic problems were also observed, affecting up to 95% of patients.
A multidisciplinary team at IUPUI is developing and testing compounds for potential treatment of hydrocephalus. They have identified a strong candidate compound that shows promise in preclinical evaluations.
A new study examines the optimal amount and intensity of physical activity for patients with heart failure with preserved ejection fraction. Higher sub-maximal exercise capacity is associated with greater quality of life, while high-intensity exercise improves maximal exercise capacity.
This article reviews mental health disorder therapeutic modalities for the GMS, highlighting effective treatments like mindfulness-based cognitive therapy and music therapy. The authors emphasize the need for trained mental health professionals and propose community-based interventions to promote a better quality of life.
Researchers developed a simple, minimally-invasive test to predict which CFTR drug works best for each patient. Nasospheroids, grown from nasal samples, are exposed to drugs and their reactions measured, offering a quick alternative to rectal biopsy.
A study of people with chronic lymphocytic leukemia (CLL) found that effectiveness and adverse events are top concerns when choosing treatment. Patients are willing to trade off some drug efficacy for reduced risk of serious side effects, but out-of-pocket costs can significantly influence their choices.
A new study found a positive association between allopurol initiation and recurring doctor visits for gout, highlighting the need for regular chronic disease reviews to evaluate patients' preferences and eligibility for treatment. The study suggests that more frequent monitoring could reduce barriers to successfully treating gout.
A national cooperative group trial is making a handful of experts in rare leukemia available around the clock to reduce high mortality rates. The goal is to decrease induction mortality from 30% to 6.7% by providing timely management and care for patients with acute promyelocytic leukemia.
A new approach, pharmacoscopy, has shown promising results in treating relapsed blood cancer. In the first clinical trial, 88.2% of patients achieved partial or complete remission with personalized therapies guided by pharmacoscopy.
A new study suggests that a breakthrough Alzheimer's treatment could leave millions of people without access to care due to the US healthcare system's limited capacity. The study identifies shortcomings in specialist diagnosis, diagnostic scanners, and infusion centers, and recommends measures to prepare for an Alzheimer's therapy.
A new study found that precision medicine for oncology is less precise for people of Latin American, African, and Asian ancestry due to the lack of diverse genetic population data. A computational tool called LumosVar was created to help researchers sort out potentially inaccurate results and improve precision medicine.
A researcher has discovered a protein that drives tumor growth in gallbladder cancer, providing an important prognostic marker for improved patient outcomes. The findings may lead to more effective treatment options and new drug therapies.
Researchers identified NOX4 enzyme as a key mechanism in kidney cancer recurrence, finding it facilitates survival of cancer cells under drug treatment. The study's findings have potential for developing targeted therapies to reverse the mechanism and prevent further disease progression.
A study published in Lancet Oncology identified MAF amplification as a tool to stratify breast cancer patients for zoledronic acid treatment. In MAF-negative patients, the inclusion of zoledronic acid improved outcomes, while non-postmenopausal MAF-positive patients experienced increased adverse outcomes.
Scientists from RUDN University have developed a new way to synthesize 1,2,4-oxadiazole derivatives, including the active ingredient of genetic disorder treatment drugs. The new method simplifies production while reducing costs and enabling high-yield synthesis without expensive reagents.
A team of researchers is working on a computer software that can deliver better therapies for patients with life-threatening heart failure. The computer model will take MRI or genetic data of a patient and build a multiscale simulation of their heart, leading to more personalized treatment plans.
Researchers found that blood pressure medication only restored normal vascular rhythms in larger vessels, leaving smallest ones unaffected. The study suggests that hypertension worsens age-related decline in microvascular function.
A team of leading European clinicians and scientists presents a unique perspective on how to move forward in the development of exon skipping therapies for DMD. The authors discuss the main challenges and opportunities for these therapeutic agents going forward, including biomarkers in AON drug development and regulatory tools in the EU.
Scientists studying cone snail venom aim to develop new medicines by understanding how the poison works. Researchers have discovered that cone snail toxins can overlap between the immune and central nervous systems in humans, potentially leading to breakthroughs in treatments for neurological diseases like Alzheimer's.
Researchers have identified a gene that may provide potential therapy for cerebral cavernous malformations (CCMs), a condition characterized by enlarged and irregular blood vessels in the central nervous system. The study suggests using angiogenesis inhibitors, such as TSP1, to treat or prevent CCMs.
Scientists have identified genetic processes that enable nerve-supporting cells to transform into specialized versions that facilitate nerve regeneration. This knowledge may lead to new drug therapies for peripheral neuropathies, a set of conditions causing numbness, muscle weakness, and sensitivity.
Researchers have created two new imaging agents that can visualize the formation of tumour-associated blood vessels and track tumour growth. These agents could provide personalized treatment options by identifying patients most likely to respond to therapies targeting new blood vessel growth, leading to more effective cancer treatment.
A new study published in Epilepsia found that cooling treatment for newborns who suffer from perinatal asphyxia significantly reduces the number of children developing epilepsy later in childhood. The research also showed improved cognitive performance, life quality, and life expectancy for these patients.
A new iPhone app called MS Mosaic aims to improve multiple sclerosis management by tracking patients' daily and weekly symptoms. The app collects data through various surveys, performance tests, and wearable device integration, providing insights for more tailored treatment.
Researchers used computational drug discovery and in vitro enzyme assays to identify potential therapeutic protein inhibitors for Chagas disease. The study successfully selected four drug-like compounds that interacted with a key amino acid, demonstrating the promise of docking simulation for identifying effective treatments.
A new drug targeting technique has been developed to target specific cells in the body, potentially improving therapies for immune-related diseases. The approach preferentially targets harmful macrophages while leaving healing cells unaffected, offering a promising solution for conditions such as arthritis and inflammatory bowel diseases.
A Mayo Clinic study found that Liraglutide slowed stomach emptying and led to significant weight loss in treated patients. The degree of stomach emptying delay was associated with the degree of weight loss, suggesting a potential biomarker for individualizing obesity treatment.
A 52-gene risk profile predicts individual patient survival for idiopathic pulmonary fibrosis (IPF) patients, improving the accuracy of current clinical tools. The study's findings have important implications for disease management and treatment decisions.
Researchers identified macrophage migration inhibitory factor (MIF) and its related protein D-dopachrome tautomerase as closely related cytokines associated with progressive MS. A genetic test could identify patients at risk of developing the disease, accelerating drug development for precision medicine.
Researchers developed a drug treatment that prevents bladder wall remodeling, significantly improving bladder compliance in dogs with spinal cord injuries. The study found long-term benefits for animals treated with the broad spectrum MMP inhibitor GM6001.
Research found that long-term heavy alcohol use affects male and female brains differently, with males showing more pronounced changes in electrical activity. The study suggests a possible mechanism for gender differences in alcohol response, highlighting the need for personalized treatment approaches.
A recent study published in the BMJ Journal of Sexually Transmitted Infections warns of the rapid increase in drug resistance of Mycoplasma genitalium (MG), a common sexually transmitted infection. The study suggests that reducing azithromycin use, currently used to treat MG, is necessary to mitigate this issue.
The PATHWAY-2 study finds that salt retention is the main cause of drug-resistant hypertension and that older diuretic medications are the most effective treatment. The research discovered that spironolactone and amiloride work equally well in lowering blood pressure, offering new alternatives for patients with resistant hypertension.
A cancer drug called bosutinib showed promise in slowing cyst growth in patients with autosomal dominant polycystic kidney disease (ADPKD). The study found a 66% reduction in kidney enlargement for those receiving bosutinib compared to placebo.
The University of Arizona Center for Integrative Medicine launched an online curriculum to train family medicine residents in integrative medicine. The 200-hour program improved residents' medical knowledge and clinical utility, with a high completion rate despite busy schedules.
Nutlin-3 targets p53-Mdm2 interaction, enhancing cancer cell growth arrest and apoptosis while producing minimal toxicity. Its potential as an alternative NPC therapy is explored in ongoing clinical trials.
A study by UC Berkeley researchers found that reference pricing is effective in reducing patient spending on prescription drugs. The policy promotes the use of cheaper alternatives over brand-name options, resulting in a 7% increase in prescriptions filled for low-price reference drugs and a 14% decrease in average price paid.
Researchers found that hypothermia can limit cell death and dynamin levels in mice with cerebral blockage. This suggests that dynamin may be a potential drug target for stroke-related neuronal cell death.
Researchers at Nemours Biomedical Research and University of Delaware have developed a patent-pending process to bridge the gap between 3D cell cultures and high throughput screening techniques. This allows for greater predictability of drug effectiveness and toxicity, leading to lower attrition rates in new medicine development.
A four-year grant will explore nanoparticle-mediated manipulation of pro- and anti-inflammatory factors to limit intestinal inflammation and promote wound healing in IBD patients.
Research reveals that many patients with chronic kidney disease experience smell loss, which correlates with poorer nutritional status. Treatment with intranasal theophylline has shown promise in improving smell function and reducing markers of malnutrition in a small group of patients.
A new study published in Clinical Infectious Diseases found that molecular tests detecting genetic mutations rendering TB resistant to drugs may be equally reliable as traditional culture-based tests in predicting treatment outcomes. The research, led by Harvard Medical School scientists, used cough secretion samples from 171 patients ...
A study by Cornell University researchers found that prolonged bisphosphonate use can alter the composition of bone, making it more brittle and susceptible to fractures. The study suggests that long-term treatment beyond FDA recommendations may increase the risk of atypical femoral fractures.
Researchers at the University of Liverpool have developed a novel approach to treating chronic myeloid leukemia (CML), which safely increases treatment success and reduces negative side effects. The study, led by Professor Richard Clark, shows that CML patients with stable responses to treatment can reduce their medication dosage befor...
A recent study published in JAMA found that patients taking cortisone for inflammation conditions have a 65% reduced risk of hip fractures when receiving the osteoporosis medication alendronate. The study analyzed over 400,000 elderly patients and found that only one in four patients received this protective treatment.